Guerbet SA (0ELV.L)
| Chiusura precedente | 18,40 |
| Aperto | 18,26 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 18,26 - 18,68 |
| Intervallo di 52 settimane | 18,26 - 18,68 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 2,299M |
| Beta (5 anni mensile) | 0,72 |
| Rapporto PE (ttm) | 0,07 |
| EPS (ttm) | 2,58 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Guerbet: 2023 Strategic Priorities
2023 Strategic Priorities Diagnostic Imaging: increase EluciremTM sales and strengthen international positionsInterventional Imaging: prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncology Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic prior
- GlobeNewswire
Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions Montpellier, France, January 11, 2023 at 6:00 PM CET Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions ("Intrasense" or the "Company") announces that the Guerbet Group (FR0000032526 - GBT) has acquired a 39% stake in its share capital through a reserved share capital increase for a total amount of 8.8 million euro
- GlobeNewswire
Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects
Guerbet announces a change in governance for its Artificial Intelligence projects Villepinte, November 3rd, 2022: Guerbet today announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018. Guerbet today announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The ter
